Pyxis Oncology, Inc.
PYXS
$2.62
$0.020.77%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 13.86M | 2.82M | 2.82M | 0.00 | 16.15M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 13.86M | 2.82M | 2.82M | 0.00 | 16.15M |
| Cost of Revenue | 2.39M | 0.00 | 0.00 | 0.00 | 475.00K |
| Gross Profit | 11.47M | 2.82M | 2.82M | 0.00 | 15.67M |
| SG&A Expenses | 19.62M | 19.44M | 19.78M | 20.40M | 22.49M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 95.70M | 85.45M | 85.73M | 83.16M | 81.72M |
| Operating Income | -81.85M | -82.63M | -82.91M | -83.16M | -65.57M |
| Income Before Tax | -78.24M | -98.97M | -98.17M | -97.40M | -79.50M |
| Income Tax Expenses | 1.39M | -1.88M | -1.88M | -2.16M | -2.16M |
| Earnings from Continuing Operations | -79.62 | -97.09 | -96.29 | -95.23 | -77.33 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -79.62M | -97.09M | -96.29M | -95.23M | -77.33M |
| EBIT | -81.85M | -82.63M | -82.91M | -83.16M | -65.57M |
| EBITDA | -77.33M | -80.47M | -80.54M | -80.75M | -62.59M |
| EPS Basic | -1.28 | -1.58 | -1.57 | -1.56 | -1.28 |
| Normalized Basic EPS | -0.79 | -0.79 | -0.79 | -0.78 | -0.61 |
| EPS Diluted | -1.28 | -1.58 | -1.57 | -1.56 | -1.28 |
| Normalized Diluted EPS | -0.79 | -0.79 | -0.79 | -0.78 | -0.61 |
| Average Basic Shares Outstanding | 248.56M | 246.77M | 244.93M | 243.51M | 233.75M |
| Average Diluted Shares Outstanding | 248.56M | 246.77M | 244.93M | 243.51M | 233.75M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |